A phase II study combining ADT, novel androgen receptor inhibitors, prostate cryoablation, and metronomic cyclophosphamide for patients with newly diagnosed, metastatic prostate cancer

Authors
Category Primary study
ConferenceEuropean Society For Medical Oncology Congress, ESMO 2025
Year 2025
This article has no abstract
Epistemonikos ID: 7bed881f2929e388617b5d0d7a40132a98a93365
First added on: May 16, 2026